abstract |
The invention relates to antibodies which treat diseases in which human IL-8, Gro-alpha, Gro-beta, Gro-gamma, GCP-2, and/or ENA-78 are implicated. The present invention relates to improved antibodies or modification thereto to treat particularly ulcerative colitis, Crohn's disease, COPD, osteoarthritis, rheumatoid arthritis, erosive arthritis, asthma, atherosclerosis, inflammatory bowel disease, psoriasis, transplant rejection, gout, cancer, acute lung injury, acute lung disease, sepsis, ARDS, peripheral artery disease, systemic sclerosis, neonatal respiratory distress syndrome, respiratory syncytial virus, flu, Behcets disease, uveitis, periodontal disease particularly gingivitis, exacerbation of asthma and COPD, cystic fibrosis, acne, Bronchiolitis obliterans syndrome, diffuse panbronchiolitis, deep vein thrombosis, preeclampsia, vasculitis, familial Mediterranean fever, reperfusion injury, pain and/or endometriosis with less inflammatory side effects. |